Heron Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes initiated coverage of Heron Therapeutics (HRTX) with a Buy rating and $6 price target Heron is a commercial-stage biotechnology company with multiple products, across the acute care and oncology supportive care setting, the analyst tells investors in a research note. The firm says Heron is entering a “meaningful inflection phase” on Zynrelef. Despite successful branded products in the post-surgical pain market, overall branded penetration remains low, contends H.C. Wainwright.